TCO conjugates and methods for delivery of therapeutic agents
AssigneesThe Research Foundation for The State University of New York, The Regents of the University of California
InventorsJose Manuel Mejia Oneto, Maksim Royzen
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.
Claims20
A solid support composition comprising:
- a biocompatible solid support;
- at least one binding agent;
- and
- a linker comprising from about 1 to about 10 linking atoms, covalently linking each binding agent to the biocompatible solid support,
- wherein the binding agent and the linker together have the structure selected from the group consisting of:
A method for selectively delivering an effective amount of a therapeutic or diagnostic agent to a first location of a targeted organ or tissue in a patient, comprising the steps of:
- (a) implanting in the patient at the first location of the targeted organ or tissue a solid support composition comprising a biocompatible solid support, a first binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the biocompatible solid support;
- and
- (b) administering to the patient a bioactive composition comprising a therapeutic or diagnostic agent, a second binding agent, and a linker comprising from about 1 to about 10 linking atoms, covalently linking the binding agent to the therapeutic or diagnostic agent, wherein the first and second binding agents bind to one another upon contact,
- wherein the therapeutic or diagnostic agent is released,
- thereby selectively delivering the effective amount of the therapeutic or diagnostic agent to the first location of the targeted organ or tissue in the patient,
- wherein the first and second binding agents are each selected from the group consisting of trans-cyclooctene and tetrazine such that one of the first and second binding agents is trans-cyclooctene and one of the first and second binding agents is tetrazine.
Dependencies are inferred from the claim text.